Trevi Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Trevi Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q3 2024.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$13.2M, a 72% decline year-over-year.
  • Trevi Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$44.3M, a 65.7% decline year-over-year.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.1M, a 0.3% increase from 2022.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$29.2M, a 14.1% increase from 2021.
  • Trevi Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$33.9M, a 3.61% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$44.3M -$13.2M -$5.54M -72% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$38.8M -$12.4M -$5.21M -72.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$33.6M -$10.9M -$4.5M -70.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 -$29.1M -$7.82M -$2.32M -42.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-20
Q3 2023 -$26.7M -$7.7M +$568K +6.87% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$27.3M -$7.15M +$907K +11.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$28.2M -$6.4M +$928K +12.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$29.2M -$5.51M +$3.02M +35.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$32.2M -$8.27M -$1.01M -13.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$31.2M -$8.05M +$1.74M +17.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$32.9M -$7.33M +$1.04M +12.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$33.9M -$8.52M +$1M +10.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$34.9M -$7.26M +$123K +1.67% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$35.1M -$9.79M -$2.41M -32.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$32.7M -$8.37M +$102K +1.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$32.8M -$9.52M -$2.99M -45.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 -$29.8M -$7.38M -$13K -0.18% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$29.8M -$7.38M -$38K -0.52% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$29.7M -$8.47M -$3.67M -76.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$26.1M -$6.54M -$555K -9.28% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$25.5M -$7.37M -$1.71M -30.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$23.8M -$7.35M -$2.49M -51.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$21.3M -$4.8M -$751K -18.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$20.5M -$5.98M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$5.65M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$4.86M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$4.05M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.